Danaher agreed to acquire Masimo for approximately $9.9 billion in cash, a deal aimed at broadening Danaher’s acute‑care diagnostics and patient monitoring footprint. The acquisition reflects strategic consolidation as large med‑tech firms push to combine monitoring hardware with diagnostic and data platforms used in hospitals. The deal follows a spate of sector M&A and multiple industry briefs that highlight shifting priorities toward integrated clinical data. Regulators and customers will watch whether the combination reshapes procurement in acute settings and how it affects competitive dynamics for monitoring and diagnostic devices.